On assessing responsiveness of health-related quality of life instruments: Guidelines for instrument evaluation

By C. Terwee, F. Dekker, W. Wiersinga, M. Prummel, P. Bossuyt. Quality of Life Research, 2003

689 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Pediatrics, Perinatology and Child Health, Pharmacology

View Paper: https://www.semanticscholar.org/paper/6b351a1b71d0f1269f1a28573389c325bc24df47

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. L. Mokkink
2. Lex M. Bouter
3. HC de Vet
4. C. Terwee
5. Jordi Alonso
6. D.walaa badawy
7. P. Stratford

In Pharmacology

1. L. Mokkink
2. Lex M. Bouter
3. HC de Vet
4. C. Terwee
5. Jordi Alonso
6. D.walaa badawy
7. D. Turk
8. D. Downham

Citations in the corpus

• Core outcome measures for chronic pain clinical trials: IMMPACT recommendations (2003, background): “Responsiveness has been defined and assessed in numerous ways, but it most often refers to the ability of a measure to detect changes over time (Guyatt et al., 1987; Terwee et al., 2003).”
• Reliability of gait performance tests in men and women with hemiparesis after stroke. (2005, methodology): “expanded (40) and data from the analyses have been used to”
• The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content (2010, background): “These measures are considered measures of the magnitude of change due to an intervention or other event, rather than measures of the quality of the measurement instrument [25,26].”
• Development and initial validation of an expanded and revised version of the Short‐form McGill Pain Questionnaire (SF‐MPQ‐2) (2009, background): “It is important to emphasize, however, that these analyses examined responsiveness to change, whatever its source, and did not evaluate whether the SF-MPQ-2 was successful in distinguishing between the active treatment and placebo, a second aspect of responsiveness required of clinical trial outcome”
• The Tinnitus Functional Index: Development of a New Clinical Measure for Chronic, Intrusive Tinnitus (2012, background): “Minimum Clinically Important Change in TFI Scores • This is an important topic and one that has generated substantial debate among measurement experts (Norman et al. 2003; Terwee et al. 2003).”
• Quality criteria were proposed for measurement properties of health status questionnaires. (2007, neutral): “Furthermore, many indices of responsiveness should actually be looked upon as measures of the magnitude of a treatment effect, which, in itself, tell us nothing about the quality of the instrument to serve its purpose [38].”
• The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. (2010, background): “[2] calculated a number of parameters for responsiveness on the same data set, for example, an effect size (ES) (as a parameter to detect clinically important change) and a receiver operator characteristic (ROC) curve (as a parameter to detect change in the construct being measured).”